ஜெஃப்ரி ந்யாப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஜெஃப்ரி ந்யாப். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஜெஃப்ரி ந்யாப் Today - Breaking & Trending Today
Share this article Share this article HOUSTON, March 4, 2021 /PRNewswire/ DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment. We are excited to clinically explore the potential of one of our immunotherapy drug candidates, which is based on our proprietary adenovirus platform technology, in additional cancer indications, said Jeffrey Knapp, chief executive officer of DNAtrix. Our preclinical work with DNX-2440 has demonstrated that infection of human tumor cell lines with this agent leads to viral replication, high level expression of OX40 ligand o ....